March 29, 2016 / 11:43 AM / in 2 years

BRIEF-Redhill Biopharma says re-submission of rizaport U.S. NDA expected in Q4 of 2016

March 29 (Reuters) - Redhill Biopharma Ltd

* Re-Submission of rizaport U.S. New drug application (NDA) to FDA and receipt of a new pdufa date are expected in Q4 of 2016 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below